T6295

Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

Ferroportin-IN-1 is an inhibitor of the iron transport protein Ferroportin, which regulates cellular iron efflux and metabolism to study diseases caused by iron-modulating deficiencies or disorders of iron metabolism, used in metabolism studies such as thalassemia, sickle cell disease, and hemochromatosis.

IRAK4-IN-18 is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) (IC50: 15 nM). It inhibits LPS-induced IL23 production in THP and DC cells and blocks the development of arthritis in rats, making it useful for studying arthritic diseases.

Aldose reductase-IN-2 (Compound 5f) is a potent aldose reductase (AR) inhibitor with antioxidant properties, making it a promising drug for anti-diabetic complications.

Estrogen receptor antagonist 5 is a potent inhibitor of the Estrogen receptor, a ligand-activated transcriptional regulatory protein that interacts with endogenous estrogens and mediates various biological effects. [Estrogen receptor antagonist 5] shows promise for studies on metastatic disease.

Estrogen receptor antagonist 6, also known as Compound 166, is a potent antagonist of the ligand-activated transcriptional regulatory protein Estrogen receptor, which interacts with endogenous estrogens to mediate various biological effects.

PARP1-IN-5 is a potent, selective, orally active, low-toxicity PARP-1 inhibitor with an IC50 value of 14.7 nM. PARP1-IN-5 can be used in cancer research.

RORγt inverse agonist 29 is a potent, selective, and orally active compound with an IC50 value of 21 nM. It can be utilized in the study of autoimmune diseases, including skin inflammation and psoriasis.

MRK-740 is a potent and selective inhibitor of PRDM9 histone methyltransferase.MRK-740 inhibits other histone methyltransferases and inhibits PRDM9-dependent H3K4 trimethylation.

SARS-CoV-2-IN-31 is a potent inhibitor of COVID-19 with excellent to mild activity (IC50: 28.84-38.36 μM) against various cancer cell lines, making it useful in cancer research.

LRH-1 modulator-1 is a potent modulator/agonist of LRH-1 (liver receptor homolog-1). LRH-1 modulator-1 induces the anti-inflammatory cytokine IL-10 and exhibits inhibition of the inflammatory cytokines IL-1b and TNFa. LRH-1 modulator-1 has anti-inflammatory activity in intestinal-like organs.